Early research (Phase 1)Not Yet RecruitingNCT07633756
What this trial is testing
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
Who this might be right for
Phase 1bOpen LabelREC-617+2 more
M.D. Anderson Cancer Center 15